Dr. Roehrl is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
330 Brookline Ave
Boston, MA 02215Phone+1 617-667-7000
Education & Training
Massachusetts General HospitalResidency, Pathology-Anatomic and Clinical, 2005 - 2009
Harvard UniversityPhD, Biological Chemistry, 1999 - 2004
Technical University Munich Faculty of MedicineClass of 1998
Certifications & Licensure
MA State Medical License 2007 - 2026
NJ State Medical License 2021 - 2023
NY State Medical License 2016 - 2023
American Board of Pathology Pathology - Anatomic/Pathology - Clinical- American Board of Pathology Clinical Informatics
Publications & Presentations
PubMed
- The role of C1orf50 in breast cancer progression and prognosis.Yusuke Otani, Atsushi Tanaka, Masaki Maekawa, Tirso Peña, Anna Rogachevskaya
Breast Cancer. 2025-03-01 - 1 citationsThe 2024 Report on the Human Proteome from the HUPO Human Proteome Project.Gilbert S Omenn, Sandra Orchard, Lydie Lane, Cecilia Lindskog, Charles Pineau
Journal of Proteome Research. 2024-12-06 - Proteomic basis for pancreatic acinar cell carcinoma and pancreatoblastoma as similar yet distinct entities.Atsushi Tanaka, Makiko Ogawa, Yihua Zhou, Ronald C Hendrickson, Matthew M Miele
NPJ Precision Oncology. 2024-10-03
Press Mentions
Michael Roehrl, MD, PhD, MBA, Joins BIDMC as Chief of PathologyApril 3rd, 2023- Behind the Study: P4HA1 Protein and Colorectal CancerNovember 22nd, 2021
Researchers Identify Novel Pathophysiologic Mechanism Responsible for AutoimmunityApril 25th, 2011- Join now to see all
Grant Support
- Evaluation of Patient Factors and Sample Pre-Analytics on Predictive Multiplex Immunohistochemical Assays in Immuno-Oncology PatientsBETH ISRAEL DEACONESS MEDICAL CENTER2023–2027
- Proteomic Characterization of Pancreatic Neuroendocrine Tumors and Metastatic ProgressionBETH ISRAEL DEACONESS MEDICAL CENTER2021–2025
- Proteomic Characterization of Pancreatic Neuroendocrine Tumors and Metastatic ProgressionBETH ISRAEL DEACONESS MEDICAL CENTER2021–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
